Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic therapy for inflammatory bowel disease.

Sandro Ardizzone1, Gabriele Bianchi Porro

  • 1Chair of Gastroenterology, L. Sacco University Hospital, Milan, Italy.

Drugs
|November 4, 2005
PubMed
Summary

The exact cause of inflammatory bowel disease (IBD) remains unknown, but research highlights the interplay of genetics, gut microbes, and environment. Biologic therapies targeting specific immune pathways show promise for treating IBD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sessile Serrated Lesions in Inflammatory Bowel Disease: Hidden Players in Colitis-Associated Colorectal Cancer?

Journal of clinical medicine·2025
Same author

Targeting of the IGFBP3/TMEM219 pathway restores intestinal stem cells capability of healing mucosa in gastrointestinal autoimmune disorders.

Pharmacological research·2025
Same author

Esophageal Squamous Papilloma and Papillomatosis: Current Evidence of HPV Involvement and Malignant Potential.

Cancers·2025
Same author

TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis.

The Journal of clinical investigation·2025
Same author

Immune-Mediated Inflammatory Diseases and Cancer - a dangerous liaison.

Frontiers in immunology·2024
Same author

Factors correlated with transmural healing in patients with Crohn's disease in long-term clinical remission on anti-TNF medication.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • The pathophysiology of inflammatory bowel disease (IBD) is not fully understood, despite advances in research.
  • Emerging evidence points to a significant role for immunogenetics, the intestinal microbiome, and environmental factors in IBD development.
  • A complex interaction between genetic predisposition, microbial influences, and environmental triggers leads to sustained mucosal immune activation and tissue damage in IBD.

Purpose of the Study:

  • To review recent data on the pathophysiology of inflammatory bowel disease (IBD).
  • To discuss the role of immunogenetics, intestinal flora, and the mucosal immune system in IBD.
  • To explore current and emerging biologic therapies targeting specific inflammatory pathways in IBD.

Main Methods:

  • Review of current literature on inflammatory bowel disease (IBD) pathophysiology.
  • Analysis of the role of genetic, microbial, and environmental factors in IBD.
  • Evaluation of biologic agents targeting cytokines, adhesion molecules, and immune cell activation for IBD treatment.

Main Results:

  • Inflammatory bowel disease (IBD) pathogenesis involves a complex interplay of genetic, microbial, and environmental factors, leading to immune dysregulation.
  • Cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukins (ILs), play a central role in mediating intestinal inflammation.
  • Several biologic agents targeting TNF, leukocyte adhesion, and T-cell activation are under investigation and show therapeutic potential for IBD.

Conclusions:

  • While the exact cause of IBD remains elusive, a multifactorial etiology involving genetic susceptibility, gut microbiota, and environmental factors is recognized.
  • Biologic therapies targeting key inflammatory mediators and immune pathways represent a promising frontier in managing IBD, with agents like infliximab already approved.
  • Ongoing clinical trials evaluating novel biologic agents offer hope for improved therapeutic strategies and better outcomes for patients with IBD.

Related Experiment Videos